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Abstract
Background: Physiotherapists (PTs) are ideally positioned to assist patients and families with inhalation therapies
through monitoring, communication and education about available therapies and their proper use; indeed
aerosoltherapy management is listed as part of Italian PTs' core competence and in the core syllabus for post-
graduate training in respiratory physiotherapy. The aim of this study was to outline the involvement of Italian PTs
working in Cystic Fibrosis (CF) centres in the aerosol delivery practice.
Methods: Physiotherapist coordinators (n = 29) of all Italian CF centres were invited to participate in a cross-
sectional survey and a semi-structured questionnaire was developed and sent by e-mail.
Results: A response rate of 69 % was achieved. The majority of participants were woman and the overall mean
professional experience was twenty years. Italian PTs are involved in the aerosol delivery practice, managing
education, drug-device combination, dilution and mixing of drugs.
Conclusions: Physiotherapists play a key role in the care of Italian CF patients; nevertheless the Italian Group of
Physiotherapists might plan interventions to harmonize the aerosol delivery practice in Italian CF centres and to
sustain continuing education.
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Background
Effective administration of aerosolized medications de-
pends on the patient’s age, physical and cognitive ability,
the delivery system and the patient-device interface [1].
Many types of inhalation devices are available for use with
various medications in Cystic Fibrosis (CF), however there
are no clinical evidences about the supremacy of one
device over another [1, 2] and few high-graded literature
on the matter [3]. Physiotherapists (PTs) are ideally posi-
tioned to assist patients and families with inhalation ther-
apies through monitoring, communication and education
about the available therapies and their proper use. Several
new drug formulations and new inhalation devices have
been developed so far for CF thus circumventing the
problem of poor penetration of intravenously adminis-
tered antibiotics into lung parenchymal tissue and bron-
chial secretions, and their potential toxicity. Given that
aerosoltherapy management is listed as part of the core
competence of Italian physiotherapists working in CF [4]
and aerosoltherapy is listed as well in the core syllabus for
post-graduate training in respiratory physiotherapy [5], we
aimed to outline the involvement of Italian PTs working
in Cystic Fibrosis centres in the aerosol delivery practice,
taking into account that Italy is the fourth European na-
tion for number of people with CF (4119, European Regis-
try 2010) and that these are followed-up in 22 referral
regional centres and in 7 support centres by 93 physio-
therapists as a whole, 29 of which are physiotherapist
coordinators.
Methods
All physiotherapist coordinators (n = 29) of Italian CF
centres were invited to participate in a cross-sectional
survey, and they were reached through the mailing list
of the Italian CF Group of Physiotherapists (ICFGP)
belonging to the Italian Society for the Study of Cystic
Fibrosis. This study was conducted during January 2014
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and data collection period lasted one week, with a gently
reminder sent after four days.
The first step was a detailed review of international lit-
erature, which allowed the selection of four topics to be
covered by the questionnaire. These four were then de-
clined in 37 items: 32 closed-ended questions, of which
5 were ordinal-polytomous, 21 nominal-polytomous and
6 dichotomous; 2 open-ended questions and 3 double-
entry tables. The first topic investigated about the profes-
sionals involved in the selection and/or administration of
aerosoltherapy (questions 4 to 10); a second topic ques-
tioned about general awareness on different devices and
their use (questions 11, 13 to 23); the third topic investi-
gated dilutions and mixtures of drugs (questions 28, 30
and 31) and the last topic investigated timing of aero-
soltherapy administration, evaluation of educational inter-
ventions and aerosol performance and tolerability as well
(questions 12, 24 to 27, 29, 32 to 37).
To determine content-related validity, two external
senior physiotherapists assessed face validity of the ques-
tionnaire and thus it was administered after two revisions.
The final form of the questionnaire included an introduc-
tory paragraph on its first page outlining the main study
aims, clarifying that participation was voluntary and assur-
ing anonymity and confidentiality of information given.
The questionnaire started with three questions about par-
ticipants’ demographics and professional experience.
Data were analysed and presented as counts or per-
centages. One open-ended question regarded the partici-
pants’ job place if different from a referral or support CF
centre; the second open-ended question was aimed to rec-
ord the name of bronchodilator used as pre-medication
during spirometry.
Results
Twenty physiotherapist coordinators from 20 centres
completed the survey. Overall response rate was 69 %,
specifically 65 % for referral regional and support centres
in the North of Italy. Seventeen centres (85 %) deal with
both paediatric and adult patients, 2 centres (10 %) with
adult and one centre (5 %) with paediatric patients only.
Non-respondents work in 9 referral regional centres,
67 % in the South and 33 % in the North of the country.
The majority of participants were woman (65 %); overall
their mean professional experience was twenty years
(ranging from 6 to 34 years).
All centres resulted to be familiar with all the available
devices for aerosoltherapy in CF: ultrasonic, jet and vi-
brating mesh nebulizers, dry-powder inhalers (DPIs) and
pressured metered dose inhalers (pMDIs) (soft mists
were excluded); only two centres declared poor familiar-
ity with ultrasonic nebulizers.
DPIs are mainly addressed to patients aged above
18 years (60 %) and 25 % of centres choose this device
for patients aged 4 years or more. Eighteen centres ad-
vice pMDIs at any age (and 10 % use a spacer or a
valved-holding chamber seldom) and two centres con-
sider this device appropriate only for patients above
18 years old. The drug-device combination as matched
by physiotherapists according to their practice is re-
ported in Table 1.
PTs demonstrate how to use aerosoltherapy devices
and educate to their proper use in 70 % of the centres.
Physicians (10 %) and nurses (10 %) are involved as well,
but always together with PTs; in one centre the phys-
ician alone is deputed to device training. Instructions for
devices assembly are given by PTs in 16 out of 20
centres (80 %). PTs are also responsible of the device
maintenance in 18 centres and in 95 % of centres PTs
are the only ones in charge of patients and care givers’
education about each aspect of inhalation therapy. In
one centre only, nurse works with physiotherapist to
educate patients’ about aerosoltherapy.
Four and three centres out of twenty reported dilution
of tobramycin and dornase alfa (Pulmozyme®) as a nor-
mal practice, respectively (Table 2). Aztreonam lysine
(Cayston®) is administered in 35 % of centres with the
vials of saline available as diluent within the package;
Promixin® 1 M IU is administered in 90 % of centres
with I-Neb® AAD system with 1 mL sterile water or ster-
ile 0.9 % saline; Colfinair® 1 M IU is diluted with 3 mL
sterile 0.9 % saline in 50 % of centres; Gluneb has an
heterogeneous administration.
Mixing is not reported as a common practice in Italian
CF centres: only 6 out of 20 centres allow mixing solu-
tions and the combination of solutions mixed is reported
in Table 3.
As regards to the timing of inhalation therapy in
relation to airway clearance techniques, almost all in-
terviewees (80 %) put short-acting bronchodilators at
the first place, followed by expectorants (65 %) before
airway clearance therapies; inhaled antibiotics were
placed afterwards (100 %), and 60 % of PTs suggested
inhalation of dornase alfa after physiotherapy and
35 % before.
Testing inhalation tolerability with spirometry is a
widespread practice in Italian CF centres: 10 % of them
check response to new inhaled formulations with pulse-
oximetry or pulmonary auscultation only. Spirometry is
done before and after the first inhalation of a new for-
mulation in 90 % of centres, and it is performed mostly
by PTs (35 %), more rarely by pulmonary function tech-
nicians (10 %) and physicians (5 %). In the remaining
half of the sample, spirometry is performed by any one
of the professionals cited above. They all administer a
short-acting beta2 agonist before inhalation, although no
homogeneity was detected about the number of puffs
delivered (from 2 to 4).
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As far as training strategies, the majority of inter-
viewees (55 %) take advantage of practical demonstra-
tions (Fig. 1) and do not give patients nor care givers
any written instruction. PTs are in charge of reviewing
inhaled therapies and how they are administered in 90 %
of CF centres, mostly during hospitalization.
Discussion
People with Cystic Fibrosis have complex care needs that
demand allied healthcare expertise. Indeed the life ex-
pectancy has increased significantly as a result of more
effective treatments in specialized CF centres [6], where
a specific knowledge and experience in the care of
children and/or adults with CF is a key factor. A physio-
therapist defined CF specialist is recommended for
providing high-quality treatment of airway clearance,
physical exercise and aerosoltherapy. Thus people with
Cystic Fibrosis should be cared for by physiotherapists
with an appropriate level of expertise in the
physiotherapy management of CF and there should be
adequate staffing levels to maintain these standards of
care too (e.g. 2 PTs caring for 50 CF patients, 3 PTs car-
ing for 150 patients or 4 PTs for ≥250 patients for a
paediatric CF centre) [6]. These specific knowledge and
skills required to PTs for dealing with respiratory diseases,
such as CF, are just some of the contents of the training
programme for respiratory physiotherapy as described by
the Respiratory Physiotherapy HERMES (Harmonising
Education in Respiratory Medicine for European Special-
ties) task force [5]. While the syllabus (available at http://
ow.ly/zYkOD) lists the core competencies that practicing
specialists in respiratory physiotherapy must possess, the
respiratory physiotherapy HERMES task force is still cur-
rently working on a comprehensive curriculum, which
provides a framework for the implementation of a post-
graduate training programme in respiratory physiotherapy
in individual countries. The advantage of fixed standards
for training, assessment and institutional accreditation has
Table 1 Drug–device combination as matched by physiotherapists during clinical practice
Dark-grey boxes show the suggested drug-device combination [10]. Percentages total can be more than 100 % because each respondent could choose more than
one combination. ¶Four centres did not answer
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the potential to safeguard practice and ensure quality care,
pushing ahead the cultural and professional growth of the
physiotherapy profession.
As outlined in the present survey, physiotherapists
play a key role in the care of Italian CF patients, from
performing inhaled therapies to educating patients and
families to their use. These results are coherent with the
role of physiotherapists involved in the respiratory care
of Cystic Fibrosis as just outlined in the European Cystic
Fibrosis Society standards of care [6], according to
which < < As CF Physiotherapists are responsible for in-
halation therapy they should be familiar with techniques,
equipment provision and appropriate maintenance of
devices> > .
Surprisingly, this survey revealed aspects such as right
drug-device combination [7], correct dilution and mix-
ing of drugs [8], which need to be urgently improved
within the Italian CF Group of Physiotherapists.
There are nebulizers that may show a faster delivery
time, but even the most effective medication cannot be
delivered properly if wrongly administered or devices are
not correctly cleaned. Variability reported in dilution
practice is a matter of concern and each centre should
discuss these differences and harmonize its own practice
according to instruction given by pharmaceutical com-
panies, keeping in mind that dilution of some drugs
makes their inhalation useless or even harmful, hamper-
ing efficacy and adherence, as a result.
Half sample should review their educational strategies,
considering that patients will experience better FEV1
with increased adherence to prescribed inhaled therapies
[9]. It is recommended indeed that education to inhaled
therapies is based on oral and written instructions [1, 2, 10],
but only 55 % of Italian CF PTs use the latter. It is responsi-
bility of the CF care team to routinely assess the educa-
tional needs of patients and family members and to
correct incomplete or incorrect information using as
many modalities as needed, such as educational bro-
chures, links to online website [11] and new technology. A
local “inhaled therapy coordinator” [9] should be iden-
tified to educate healthcare professionals and patients
in addition to running periodic evaluations; it is
Table 2 Drug–dilution practice as performed by physiotherapists in CF centres
Dark-grey boxes show suggested drug dilution, as reported in patient information leaflets and/or by pharmaceutical companies. Percentage total for
Colistimethate sodium (Promixin® 1 M IU) is more than 100 % because two centres gave more options
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suggested that patients should be evaluated one
month after treatment has started and regularly
assessed afterwards [7], at least annually by a CF
specialist physiotherapist [10]. Even if a spirometry
[4, 10], an assessment of breathlessness and sense of
well-being [9] are the only measures suggested, espe-
cially if inhaled antibiotics, dornase alfa and
hypertonic saline are administered [10], no guideline
on the matter is available at the moment on lung func-
tion test practice in CF.
As the present study was designed as an electronic
survey, there are important limitations concerning data
interpretation: one week only was allowed for the com-
pletion of questionnaire and only physiotherapist
Fig. 1 Educational strategies adopted by Physiotherapists
Table 3 Inhalation solutions/suspensions allowed to be mixed in 6 out of 20 centres
SABA – short-acting beta2 agonist; LABA – long-acting beta2 agonist
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coordinators were involved, maybe inaccurately repre-
senting the real practice of aerosol delivery as done in
their centres.
Conclusion
To our knowledge, this is the first time that involvement of
physiotherapists in aerosoltherapy practice was investigated
in Italian CF centres. The findings of the present study indi-
cated the leading role of physiotherapists in aerosol delivery
practice in the Cystic Fibrosis care but showed a worrisome
and inhomogeneous behaviour among CF centres, requir-
ing urgent revision.
The Italian CF Group of Physiotherapists might plan
interventions to harmonize the aerosol delivery practice
in CF centres and to sustain continuing education of
physiotherapists and of all other professionals involved
in fostering patients’ education. New drugs and devices
are being placed on the market and it is one of the du-
ties of CF physiotherapists to continue to deepen their
knowledge and acquire new ones in this field.
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